EP1347776A2 - Utilisations de composes polycationiques - Google Patents
Utilisations de composes polycationiquesInfo
- Publication number
- EP1347776A2 EP1347776A2 EP02702238A EP02702238A EP1347776A2 EP 1347776 A2 EP1347776 A2 EP 1347776A2 EP 02702238 A EP02702238 A EP 02702238A EP 02702238 A EP02702238 A EP 02702238A EP 1347776 A2 EP1347776 A2 EP 1347776A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cpg
- poly
- arginine
- odn
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 50
- 230000003110 anti-inflammatory effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 27
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 229930010555 Inosine Natural products 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 69
- 239000002158 endotoxin Substances 0.000 description 47
- 229920006008 lipopolysaccharide Polymers 0.000 description 45
- 210000004443 dendritic cell Anatomy 0.000 description 42
- 238000002347 injection Methods 0.000 description 42
- 239000007924 injection Substances 0.000 description 42
- 108090001005 Interleukin-6 Proteins 0.000 description 39
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 39
- 102100040247 Tumor necrosis factor Human genes 0.000 description 39
- 238000004519 manufacturing process Methods 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 29
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 239000000126 substance Substances 0.000 description 28
- 230000009885 systemic effect Effects 0.000 description 25
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000000770 proinflammatory effect Effects 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 13
- 241001529936 Murinae Species 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 108010007004 cathelin Proteins 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005923 long-lasting effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920001917 Ficoll Polymers 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229920002851 polycationic polymer Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007108 local immune response Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 108060001132 cathelicidin Proteins 0.000 description 2
- 102000014509 cathelicidin Human genes 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MEXAGTSTSPYCEP-NUBCRITNSA-N (2r)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@@H](N)C(O)=O MEXAGTSTSPYCEP-NUBCRITNSA-N 0.000 description 1
- ZYECOAILUNWEAL-NUDFZHEQSA-N (4z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-n-(3-nitrophenyl)-3-oxonaphthalene-2-carboxamide Chemical compound COC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1N\N=C(C1=CC=CC=C1C=1)/C(=O)C=1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 ZYECOAILUNWEAL-NUDFZHEQSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241001664542 Karima Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- -1 pR60 Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to new uses for polycationic compounds.
- polycationic compounds for example the polycationic amino acid polymers poly-L-arginine and poly-L-ly- sine, have been shown to allow very efficient charging of antigen presenting cells (APCs) with antigens in vitro and in vivo. This is thought to be the key event for triggering immune cascades, eventually leading to the induction of antigen specific immune effector cells that are able to destroy or neutralise targets. It has been shown previously that a number of polycationic compounds excert effects on immune cells (Buschle et al . , Gene Ther.Mol.Biol. 1 (1998), 309-321; Buschle et al . , Proc.Natl.Acad.Sci. USA, 94 (1997), 3256-3261).
- Co-injection of a mixture of poly-L-arginine and poly-L-lysine together with an appropriate antigen as a vaccine protect animals from tumor growth in several animal models.
- a vaccine consisting of polycationic compounds and antigens is accepted in the art as being a very effective form of treatment (WO 97/30721) .
- polycationic compounds may be used to prevent inflammatory effects in an individual having or being at risk of inflammation or, alterna- tively, to reduce the inflammatory potential of a medicament or a medical treatment significantly which allows the administration of medicaments that are usually not administered or only rarely administered due to their inflammatory side-effects.
- This anti-inflammatory effect of polycationic compounds used according to the present invention may be observed both locally and systemically.
- the present invention is especially beneficial if the combined medicament is administered, e.g. subcutaneously, intravenously, intranasally, intramusculary, intradermally or transdermally.
- other application forms such as parenteral or topical application, are also suitable for the present invention.
- the depot effect seems to be mostly significant if the composition is injected or implanted.
- the antigen to be used within the course of the present invention is not critical, it may preferably be selected from the group consisting of an antigen from a viral or a bacterial pathogen, an antigen from an eucaryotic pathogen, a tumor antigen, an autoimmune antigen or mixtures thereof. Especially preferred are negatively charged antigens or hydrophobic antigens . Further examples of antigens are whole-killed organisms, such as inactivated viruses or bacteria, fungi, protozoa or even cancer cells. Antigens may also consist of subfractions of these organisms/tissues, of proteins, or, in their most simple form, of peptides.
- Antigens can also be recognised by the immune system in form of glycosy- lated proteins or peptides and may also be or contain polysaccha- rides or lipids.
- Short peptides can be used, since e.g. cytotoxic T cells (CTL). recognise antigens in form of short usually 8-11 a ino acids long peptides in conjunction with major histocompati- bility complex (MHC) .
- MHC major histocompati- bility complex
- B cells recognise longer peptides starting at around 15 amino acids. By contrast to T cell epitopes, the three dimensional structure of B cell antigens may also be important for recognition by antibodies .
- Preferred pathogens are selected from human immune deficiency virus (HIV) , hepatitis A and B viruses, hepatitis C virus (HCV) , Rous sarcoma virus (RSV) , Epstein Barr virus (EBV) , Influenza vi- rus, Rotavirus, Staphylococcus aureus, Chlamydia pneumoniae, Chlamydia trachomatis, Mycobacterium tuberculosis, Streptococcus pneumoniae, Bacillus anthracis, Vibrio cholerae, Plasmodium sp.
- HCV human immune deficiency virus
- HCV hepatitis A and B viruses
- HCV hepatitis C virus
- RSV Rous sarcoma virus
- EBV Epstein Barr virus
- Influenza vi- rus Influenza vi- rus
- Rotavirus Staphylococcus aureus
- Chlamydia pneumoniae Chlamydia
- Antigens may also be molecules expressed by cancer cells
- Antigens may also be derived antigens.
- the derivation process may include the purification of a specific protein from the pathpgen/cancer cells, the inactivation of the pathogen as well as the proteolytic or chemical derivatisation or stabilisation of such a protein.
- tumor antigens cancer vaccines
- autoimmune antigens may be used together with a polycationic compound according to the present invention.
- the polycationic compound (s) to be used according to the present invention may be any polycationic compound, which shows e.g. the characteristic effect according to the WO 97/30721, or others like cationic liposomes, polyethylene-a ine, chitosan, poly cations used for DNA transfer, etc..
- Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyaminoacids or mixtures thereof. These polyaminoacids should have a chain length of at least 4 amino acid residues (see: Tuft- sin as described in Goldman et al (1983)) .
- substances containing peptidic bounds like polylysine, polyarginine and polypeptides containing more than 20%, especially more than 50% of basic amino acid residues in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof .
- Other preferred polycations and their pharmaceutical compositons are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528.
- these polypeptides contain between 5 and 500 amino acid residues, especially between 10 and 200 residues.
- polycationic compounds may be produced chemically or reco - binantly or may be derived from natural sources .
- Cationic (poly) peptides may also be polycationic anti-bacterial microbial peptides with properties as reviewed in (Ganz and Le- hrer, 1999; Hancock, 1999). These (poly)peptides may be of pro- karyotic or animal or plant origin or may be produced chemically or recombinantly (Andreu and Rivas , 1998; Ganz and Lehrer, 1999; Simmaco et al . , 1998) . Peptides may also belong to the class of defensins (Ganz, 1999; Ganz and Lehrer, 1999).
- Such host defense peptides or defensines are also a preferred form of the polycationic polymer according to the present invention.
- a compound 'allowing for activation (or down- regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.
- cathelicidin derived anti- icrobial peptides or derivatives thereof are especially preferred for use as polycationic substance in the present invention.
- anti-microbial peptides derived from mammal cathelicidin preferably from human, bovine or mouse.
- Polycationic compounds derived from natural sources include HIV- REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombi- nant production.
- Other preferred polycationic compounds are cathelin or related or derived substances from cathelin.
- mouse cathelin is a peptide which has the amino acid sequence NH2-RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-COOH.
- Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues.
- Derivations may include the substitution or modification of the natural amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules . These cathelin molecules are preferred to be combined with the antigen and the immunogenic ODNs according to the present invention. However, these cathelin molecules surprisingly have turned, out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without fur- ther immunostimulatory substances.
- CpG-ODNs promotes the induction of a Thl-type response and the development of cytotoxic T cells.
- immu- nogenic ODNs are used as vaccine adjuvants to enhance the antibody response to specific antigens (e.g. EP 0 468 520 A2 , WO 96/02555, WO 98/16247, etc.).
- specific antigens e.g. EP 0 468 520 A2 , WO 96/02555, WO 98/16247, etc.
- these CpG-ODNs exhibit strong inflammatory potential, an administration of CpG-ODNs is connected with severe local and systemic inflammatory events.
- CpG-ODNs show local as well as systemic inflammatory reactions, but at the same time have also a potential to be used as a beneficial stimulatory medicament, this substance was applied to an animal to create and provide a model to show the advantages of the present invention. Indeed, it could be shown that both, the local and the systemic inflammatory events caused by administration of CpG-ODNs may be completely inhibited by administration of polycationic compounds .
- a preferred embodiment of the present invention is characterised in that the medicament is to be applied together with the polycationic compound further comprises immunogenic oli- godesoxy nucleic acid molecules (ODNs) , especially ODNs containing CpG motifs (CpG-ODNs) , inosine containing ODNs (I-ODNs) or mixtures or combinations thereof.
- ODNs immunogenic oli- godesoxy nucleic acid molecules
- CpG-ODNs ODNs containing CpG motifs
- I-ODNs inosine containing ODNs
- this strong local immune response (day 4/draining lymph node cells) induced after one single injection of an anti ⁇ gen with a mixture of polycationic compounds (as an example polyarginine pR 60 is used) and CpG-ODNs converts to a systemic immune response which is very long lasting.
- the complex formation ability of substances such as CpG-ODNs with polycationic compounds is used for preventing a systemic distribution and the subsequent fast resorption of such substances, thereby providing a strong prolongation of the properties of such substances, e.g. a prolongation of the immu- nostimulatory properties of CpG-ODNs.
- preventing the systemic distribution avoids the induction of potential harmful systemic side effects of immunostimulatory agents.
- This model using CpG-ODNs and polycationic peptides is f ⁇ rther described and analysed in the example section.
- an Ovalbumin-derived peptide OVA257-26-
- a model compound a model antigen
- a second preferred compound with inflammatory potential to be used within the course of the present invention is lipopolysac- charide (LPS, endotoxin) , a cell wall component of Gram-negative bacteria.
- LPS lipopolysac- charide
- endotoxin a cell wall component of Gram-negative bacteria.
- LPS plays a pivotal role in the induction of septic shock (endotoxic shock) (Karima et al (1999) .
- septic shock endotoxic shock
- leukocyte-induced tissue injury and activation of coagulation systems appear to be critical determinants in the development of sequential organ failure.
- lethal shock can be associated with excessive secretion of pro-inflammatory cytokines like TNF-a and IL-6.
- the present invention also relates to a method for treating or preventing inflammation, comprising administering to an individual (e.g. Patient or animal), suffering from inflammation or being at risk thereto, an effective amount of a polycationic compound.
- the invention further relates to a method for reducing the inflammatory potential of a medicament when administering said medicament to a patient, comprising administering that medicament together with an effective amount of a polycationic compound.
- polycationic compound to be administered is highly depending on the necessities of the individual composition and optionally on the drug to be administered together with the polycationic polymer.
- preferred amounts of polycation are 0.001-1000 ⁇ g/administration unit, more preferred 0,1-10 mg/dose, especially around or beyond 0,1 mg/20g body weight (of mice) or the equivalent dose for humans .
- Fig. 1 shows that the combined application of poly-L-arginine, CpG-ODN and antigen induces strong antigen-specific immune responses which are systemic and very long lasting.
- the figure shows peripheral blood lymphocytes stimulated ex vivo with OVA257- 264-peptide;
- Fig. 2a shows that poly-L-arginine induces the formation of a depot, at the injection site.
- This figure shows photos from the injection sites at the indicated time points after vaccination.
- White lines surround the area where the fluorescence labelled compounds of the vaccine can be detected;
- Fig. 2b shows that the co-application of poly-L-arginine inhibits the spreading of CpG-0DN-Cy5 throughout the body.
- This figure shows FACS analyses of lymphoid and non-lymphoid tissues at day 1 after injection of CpG-ODN-Cy5 (B) or CpG-ODN-Cy5 and pR 60-FITC (C) . Untreated mice were used as a control (A) ;
- Fig. 3 shows that poly-L-arginine induces the formation of a depot at the injection site when co-injected at least with one more molecule. This figure shows photos from the injection sites at day 4 after vaccination;
- Fig. 4 shows that co-injected poly-L-arginine prevents the CpG- ODN-induced systemic production of TNF- ⁇ and IL-6 in vivo.
- Mice were injected into the hind footpads and one hour later serum was prepared. The amount of TNF- ⁇ and IL-6 in the sera was determined by ELISA;
- Fig. 5 shows that poly-L-arginine abrogates CpG-ODN-induced production of TNF- ⁇ and IL-6 by mouse BM-DC in vitro.
- CDllc + sorted BM-DC were incubated either with pR60, CpG-ODN 1668 or pR60 and CpG-ODN 1668 or, for control purposes, with.medium or LPS. After the incubation for 24 h, the amount of TNF- ⁇ and IL-6 were determined in the supernatant by ELISA;
- Fig. 6 shows that poly-L-arginine abrogates poly I:C-induced production of pro-inflammatory cytokines by human DC in vitro.
- Day 5-cultured human monocyte-derived DC were incubated (lxlOVwell) either with poly I:C, pR60, poly I:C and pR60 or, for control purposes, with LPS and medium alone in 24-well culture plates for 24 h. Thereafter, supernatants were collected and stored at -2p°C until use. The amount of TNF- ⁇ and IL-6 in the supernatants was determined by ELISA.
- Fig.7 shows that KLK abrogates CpG-ODN-induced production of TNF- ⁇ and IL-6 by BM-DC in vitro: CD llc + sorted BM-DC were incubated either with KLK, CpG-ODN 1668 or KLK and CpG-ODN 1668 or, for control purposes, with medium or LPS. After the incubation for 24 h, the amount of TNF- ⁇ and IL-6 in the supernatants were determined by ELISA.
- Fig.8 shows that co-injected poly-L-arginine prevents the BCG/CpG-ODN-induced systemic production of TNF- ⁇ and IL-6 in vivo.
- Mice were injected s.c. Into the flank with 5xl0 3 cells of BCG and one hour later serum was prepared. The amount of TNF- ⁇ and IL-6 in the sera was determined by ELISA.
- Fig.9 shows that poly-L-arginine decrease LPS-induced production of pro-inflammatory cytokines by murine bone-marrow-derived dendritic cells in vitro.
- Fig.10 shows that poly-L-arginine, KLK and poly-D-lysine decrease LPS-induced production of pro-inflammatory cytokines by human dendritic cells in vitro.
- fluorescence-labeled compounds were injected together subcutaneously into the flank of mice. At different time points after this treatment, injection sites were inspected for the presence of labeled compounds.
- OVA 25 7-264-peptide unlabeled
- poly-L-arginine- FITC yellow
- CpG-ODN-Cy5 blue
- CpG-ODN-Cy5 is also detectable in secondary lymphoid organs (draining lymph node, spleen) and non-lymphoid tissues (lung, liver, kidney, heart) .
- TRP-2i8i-i88-peptide-FITC yellow
- poly-L ⁇ arginine-TRITC red-violet
- CpG-ODN-Cy5 blue
- TRP-2 ⁇ s ⁇ - i88-peptide-FlTC was injected either alone or in combination with CpG-ODN-Cy5
- the peptide was not detectable at the injection site at day 4.
- CpG-ODNs are described to have potentially harmful side effects in that they induce the systemic release of high amounts of pro-inflammatory cytokines such as TNF- ⁇ and IL-6, which could induce a shock syndrome (Sparwasser 1997, Lipford 1997).
- cytokines such as TNF- ⁇ and IL-6
- Sparwasser 1997, Lipford 1997 a shock syndrome
- CpG-ODNs are not systemically present when injected in combination with poly-L-arginine. Therefore, it was investigated whether the co-administration of poly-L-arginine affects the CpG-ODN-induced systemic production of TNF- ⁇ and IL-6. Serum levels of both cytokines were determined by ELISA one hour after injection.
- Example 4 demonstrates that neither the injection of OVA 2 57-264-peptide alone nor in combination with poly-L-arginine led to the induction of significant amounts of TNF- ⁇ and IL-6 in the serum, whereas the injection of OVA 2S 7-264-peptide in combination with CpG-ODN induces high concentrations of both cytokines. However, upon co-administration of OVA 2 57-264-peptide with poly-L-arginine and CpG-ODN, this systemic production of TNF- ⁇ and IL-6 was totally abolished.
- CDllc + dendritic cells were incubated either with poly-L-arginine, CpG-ODN or the combination of poly-L- arginine and CpG-ODN (example 5) .
- the levels of TNF- ⁇ and IL-6 were determined in the supernatants derived from these cultures.
- After incubation with poly-L-arginine neither TNF- ⁇ nor IL-6 were detectable, whereas after incubation with CpG-ODN significant amounts of both cytokines are produced.
- the presence of poly-L-arginine inhibited the CpG-ODN-induced production of TNF- ⁇ and IL-6 by these cells.
- poly-L-arginine also inhibits the polyinosinic-polycytidylic acid-induced production of pro-inflammatory cytokines by human dendritic cells (Example 6) .
- Ovalbumin-peptide/poly-L-arginine (pR 60)/ CpG-ODN leads to the induction of strong antigen-specific immune responses which are systemic and very long lasting.
- Peptide OVA 25 7-264-Peptide (SIINFEKL) , a MHC class I (H-2Kb)- restricted epitope of chicken Ovalbumin (Rotz- schke, 0. et al . , Eur. J. Immunol. 1991 21 (11): 2891-4) , synthesised by standard solid phase F- moc synthesis, HPLC purified and ana lysed by mass spectroscopy for purity. Dose: 300 ⁇ g/mouse
- mice mice per group.
- OVA 2 57-264-Pe tide CpG-ODN + pR 60
- OVA 25 7-264-Peptide CpG-ODN 3 "
- mice were injected into each hind footpad with a total volume of lOO ⁇ l (50 ⁇ l per footpad) containing the above mentioned compounds .
- Blood was taken via the tail vein at the indicated time points and peripheral blood lymphocytes (PBLs) were isolated using a Ficoll gradient. PBLs were stimulated ex vivo with the antigen used for vaccination, with medium (background) and Conca- navalin A (positive control) .
- IFN- ⁇ -ELISPOTs were carried out as described (Miyahira et al . , 1995). This method is a widely used procedure allowing the quantification of antigen-specific T cells. Spots representing single IFN- ⁇ producing T cells were counted and the number of background spots was substracted from all samples. There were many spots detected after the stimulation with Con A (data not shown) indicating a good condition of the used lymphocytes. For each experimental group of mice the number of spots/lxlO 6 PBLs are illustrated in Figure 1.
- Example 2a Example 2a
- Poly-L-arginine induces the formation of a depot at the injection site
- Peptide OVA 25 7-264-Peptide (SIINFEKL) , a MHC class I (H- 2Kb) -restricted epitope of chicken Ovalbumin (Rotzschke, O.et al . , Eur. J. Immunol. 1991 21(11): 2891-4), synthesised by standard solid phase F-moc synthesis, HPLC purified and analysed by mass spectroscopy for purity. Dose: 300 ⁇ g/mouse
- FITC fluorescein
- mice On day 0 mice were injected subcutaneously into the right flank with a total volume of lOO ⁇ l containing the above mentioned compounds. Animals were sacrificed at the indicated time points after injection and photos were taken from the injection sites (Fig. 2a) .
- FITC fluorescein
- mice were injected subcutaneously into the right flank with a total volume of lOO ⁇ l containing the above mentioned compounds.
- mice were sacrificed and FACS-analyses were performed from secondary lymphoid organs (draining lymph node, spleen) as well as non-lymphoid tissues (lung, liver, kidney, heart) (Fig. 2b) .
- Poly-L-arginine induces the formation of a depot at the injection site when co-injected at least with one more molecule
- TRP-2-Peptide VYDFFVWL
- H-2Kb MHC class I
- HPLC HPLC purified and analysed by mass spectroscopy for purity.
- fluorescein (FITC) labeling the TRP-2 ⁇ 8 ⁇ -i88-peptide was dissolved in 1M sodium borate, pH 7,9. An 8-fold molar excess of FITC (Molecular Probes, Eugene, OR) in an equal volume of DMF was added to the peptide solution.
- SIGMA chemi- cals For TRITC-labeling ' of poly-L-arginine, the poly-L-arginine was dissolved in 50mM HEPES pH 7,9 (10mg/500 ⁇ l) . A 5-fold molar excess of FITC (Molecular Probes, Eugene, OR) in an equal volume of DMSO was added to the poly-L-arginine solution. The solution was kept at room . temperature in the dark for.2 , 5 hours .
- mice On day 0 mice were injected subcutaneously into the right flank with a total volume of lOO ⁇ l containing the above mentioned compounds. Animals were sacrificed at day 4 after injection and photos were taken from the injection sites (Fig. 3) .
- Peptide OVA257-264 (SIINFEKL) , an MHC class I (H-2Kb) -restricted epitope of chicken ovalbumin (Rotzschke et al . , 1991), was synthesised using standard solid phase F-moc synthesis, HPLC-purified and analysed by mass spectroscopy for purity Dose: 300 ⁇ g/mouse
- CpG-ODN 1668 phosphothioate-modified oligodeoxynucleotides containing a CpG motif TCC ATG ACG TTC CTG ATG CT, synthesised by NAPS GmbH, G ⁇ ttingen. Dose: 5 nmol/mouse
- mice were injected into each hind footpad with a total volume of lOO ⁇ l (50 ⁇ l per footpad) , containing the above mentioned compounds.
- lOO ⁇ l 50 ⁇ l per footpad
- Poly-L-arginine abrogates CpG-ODN-induced production of pro-inflammatory cytokines by murine bone marrow-derived dendritic cells in vitro
- Murine dendritic cells were generated from bone-marrow precursor cells of C57B1/6 mice as previously described (Inaba 1992) . Briefly, bone marrow cells were obtained by flushing the femurs and tibias with medium. Cells were depleted of lymphocytes, granulocytes and MHC class II + cells by Ab-complement-me- diated lysis. Dead cells were removed by Ficoll gradient (Ficoll Separating Solution, density l,077g/mol; Biochrom KG, Germany).
- the remaining cells (1 x lOVml) were cultured in 24-well culture plates in high glucose DMEM medium (PAA Laboratories GmbH, Linz, Austria; E 15-009) supplemented with 10% heat-inactivated FCS, 10 mM sodium pyruvate, 2mM L-glutamine, 50mg/ml gentamicin, 0,5mM 2-mercaptoethanol (all supplements from PAA Laboratories GmbH, Linz, Austria), 20ng/ml GM-CSF and 250 U/ml IL-4. On day 3 of culture, cells were fed with fresh medium.
- CDllc + sorted BM-DC were incubated either with poly-L-arginine (lO ⁇ g/ml) , CpG-ODN 1668 (lnmol/ml) or the combination of poly-L- arginine and CpG-ODN 1668, and, for control purposes, with medium or LPS.
- Supernatants were harvested after 24h and analysed for the production of TNF- ⁇ and IL-6 using specific ELISAs .
- CpG-ODN 1668 induces the production of TNF- ⁇ and IL-6 by murine BM-DC ( Figure 5) .
- murine BM-DC were stimulated with poly-L-arginine alone, we could not detect any of the mentioned pro-inflammatory cytokines in DC-derived supernatants .
- the CpG-ODN 1668-induced production of TNF- ⁇ and IL-6 was inhibited when BM-DCs were stimulated with a mixture of " CpG- ODN 1668 and poly-L-arginine.
- Poly-L-arginine abrogates poly I:C-induced production of pro-inflammatory cytokines by human DC.
- PBLs peripheral blood leukocytes
- CD14-coated magnetic beads Miltenyi Biotec Inc., Germany
- Example 7 KLK abrogates Cpg-ODN-induced production of pro-inflammatory cytokines by murine bone marrow-derived dendritic cells in vitro.
- LPS Lipopolysaccharide
- Escherichia coli Lipopolysaccharide from Escherichia coli; serotype 0111 :B4 (SIGMA Chemicals)
- Murine dendritic cells were generated from bone-marrow precursor cells of C57B1/6 mice as described in example 5.
- CDllc + sorted BM-DC were incubated either with KLK (16,8 ⁇ g/ml), CpG-ODN 1668 (0,5nmol/ml) or the combination of poly-L-arginine and CpG-ODN 1668, and, for control purposes, with medium or LPS.
- Supernatants were harvested after 24h and analysed for the production of TNF-a and IL-6 using specific ELISAs.
- CpG-ODN 1668 induces the production of TNF-a and IL-6 by murine BM-DC ( Figure 7) .
- murine BM-DC were stimulated with KLK alone, we could not detect any of the mentioned pro-inflammatory cytokines in DC-derived supernatants.
- the CpG-ODN 1668-induced production of TNF-a and IL-6 was inhib- ited when BM-DCs were stimulated with a mixture of CpG-ODN 166S and KLK.
- Example 8 The co-injection of poly-L-arginine prevents the BCG/CpG-ODN-induced systemic production of TNF-a and IL-6 in vivo.
- mice C57B1/6 (Harlan/Olac) Vaccine BCG (Bacille Calmette Guerin) - Vaccine "Pasteur Merieux” ; -live vaccine, containing an attenuated strain of Mycobacterium bovis; (Pasteur Merieux Connaught Austria)
- Poly-L-arginine 60 (pR60) Poly-L-arginine with an average degree of polymerization of 60 arginine residues; SIGMA Chemicals Dose: lOO ⁇ g/mouse
- CpG-ODN 1668 phosphothioate-modified oligode- oxynucleotides containing a CpG motif TCC ATG ACG TTC CTG ATG CT, synthesized by NAPS GmbH, G ⁇ ttingen. Dose: 5 nmol/mouse
- mice were injected subcutaneously into the flank with a total volume of lOO ⁇ l, containing the above mentioned compounds.
- the amount of the pro-inflammatory cytokines TNF-a and IL-6 in the sera was determined by cytokine-specific ELISAs according to the manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN) .
- This experiment shows that injection of BCG alone or in combination with poly-L-arginine does not induce the production of significant amounts of TNF-a or IL-6 ( Figure 8) .
- the injection of CpG-ODN 1668 alone or in combination with BCG induces the systemic production of TNF-a and IL-6.
- the BCG vaccine' and CpG-ODN were co-injected with poly-L-arginine, the CpG-ODN-induced production of pro-inflammatory cytokines was inhibited.
- Example 9 Poly-L-arginine decrease LPS-induced production of pro-inflammatory cytokines by murine bone-marrow-derived dendritic cells in vitro.
- LPS Lipopolysaccharide
- Poly-L-arginine 60 (pR60) Poly-L-arginine with an average degree of polymerization of 60 arginine residues; SIGMA Chemicals,
- Murine dendritic cells were generated from bone-marrow precursor cells of C57B1/6 mice as described in example 5.
- the LPS-induced production of TNF-a and IL-6 was inhibited when BM-DCs were stimulated with a mixture of LPS/poly-L- arginine or when the cells were pre-incubated with poly- Larginine .
- Example 10 Poly-L-arginine, KLK and poly-D-lysine decrease LPS- induced production of pro-inflammatory cytokines by human dendritic cells in vitro.
- LPS Lipopolysaccharide
- Poly-L-arginine 60 (pR60] Poly-L-arginine with an average degree of polymerizaTion of 60 arginine residues; SIGMA Chemicals,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02702238A EP1347776A2 (fr) | 2001-01-05 | 2002-01-07 | Utilisations de composes polycationiques |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2001/000087 WO2001054720A1 (fr) | 2000-01-28 | 2001-01-05 | Composition pharmaceutique pour immunomodulation et preparation de vaccins comprenant un antigene, un oligodesoxyribonucleotide immunogene et polymere polycationique sous forme d'adjuvants |
WOPCT/EP01/00087 | 2001-01-05 | ||
AT6702001 | 2001-04-25 | ||
AT6702001 | 2001-04-25 | ||
PCT/EP2002/000071 WO2002053185A2 (fr) | 2001-01-05 | 2002-01-07 | Utilisations de composes polycationiques |
EP02702238A EP1347776A2 (fr) | 2001-01-05 | 2002-01-07 | Utilisations de composes polycationiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1347776A2 true EP1347776A2 (fr) | 2003-10-01 |
Family
ID=25608381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02702238A Withdrawn EP1347776A2 (fr) | 2001-01-05 | 2002-01-07 | Utilisations de composes polycationiques |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1347776A2 (fr) |
JP (1) | JP2004519453A (fr) |
WO (1) | WO2002053185A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2484941A1 (fr) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigenes a phase de lecture alternante a partir de virus |
JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | C型肝炎ウイルスペプチドの単離方法 |
AU2004224747A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Use of Alum and a th1 immune response inducing adjuvant for enhancing immune responses |
EP1608402B1 (fr) * | 2003-03-24 | 2010-10-20 | Intercell AG | Vaccins ameliores |
KR20080034973A (ko) | 2005-07-29 | 2008-04-22 | 산또리 가부시키가이샤 | 후코이단 또는 후코이단 가수분해 생성물과 면역 부활소재를 함유하는 조성물 |
CN102639142A (zh) | 2009-09-16 | 2012-08-15 | 杜克大学 | 内体Toll样受体活化的抑制 |
WO2011101465A1 (fr) | 2010-02-19 | 2011-08-25 | Intercell Ag | Nanoparticules d'ic31 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1290141A (fr) * | 1968-05-31 | 1972-09-20 | ||
JPH09176038A (ja) * | 1995-09-18 | 1997-07-08 | Hisamitsu Pharmaceut Co Inc | 抗炎症性アンチセンス薬物 |
CO4600681A1 (es) * | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
EP1089755B1 (fr) * | 1998-06-26 | 2004-02-18 | N.V. Nutricia | Preparations pharmaceutiques destinees a combattre ou a prevenir les infections superficielles provoquees par des micro-organismes |
JP2000256196A (ja) * | 1999-03-05 | 2000-09-19 | Pias Arise Kk | 抗炎症,抗アレルギー剤 |
ES2228497T3 (es) * | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
ATE249839T1 (de) * | 2000-06-08 | 2003-10-15 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Immunstimulierende oligodeoxynukleotide |
-
2002
- 2002-01-07 EP EP02702238A patent/EP1347776A2/fr not_active Withdrawn
- 2002-01-07 JP JP2002554134A patent/JP2004519453A/ja active Pending
- 2002-01-07 WO PCT/EP2002/000071 patent/WO2002053185A2/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO02053185A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002053185A2 (fr) | 2002-07-11 |
WO2002053185A3 (fr) | 2002-10-31 |
JP2004519453A (ja) | 2004-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080025996A1 (en) | Methods and Compositions Comprising Polycationic Compounds | |
AU784403B2 (en) | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants | |
EP1326634B1 (fr) | Composition vaccinale comprenant un antigene et un peptide ayant des proprietes adjuvantes | |
EP1286695B1 (fr) | Composition antigenique comprenant un peptide polycationique et inosine et cytosine | |
EP1296713B1 (fr) | Oligonucleotides synthetiques immunostimulatoires | |
AU2002212326A1 (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
US20040248831A1 (en) | Immunostimulatory oligodeoxynucleic molecules | |
JP2008222721A6 (ja) | ワクチン組成物 | |
EP1347776A2 (fr) | Utilisations de composes polycationiques | |
EP1347775B1 (fr) | Utilisation de substances polycationiques en tant qu'adjuvants pour vaccins | |
US20040081655A1 (en) | Methods and compositions comprising polycationic compounds | |
AU2002235820A1 (en) | Anti-inflammatory use of polycationic compounds | |
AU2002233302A1 (en) | Uses for polycationic compounds as vaccine adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030723 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CISTEM BIOTECHNOLOGIES GMBH Owner name: INTERCELL AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INTERCELL BIOMEDIZINISCHE FORSCHUNGS- UND ENTWICKL Owner name: INTERCELL AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INTERCELL AG |
|
17Q | First examination report despatched |
Effective date: 20070312 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090815 |